The NACE Clinical Highlights Show

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/responding-to-the-science-biologics-in-practice-in-copd-10511 Summary This enduring podcast activity provides pulmonologists and clinicians managing COPD with timely updates on the evolving role of biologics management. Featuring expert discussions, the program explores recent GOLD guideline revisions, the integration of new and emerging biologic therapies, and evidence-based decision-making based on clinical trial data and real-world practice. Covering guidelines, clinical trials, and clinical scenario, this activity emphasizes the translation of complex data into practical strategies. Learners will gain improved knowledge and competence related to patient selection, eosinophil thresholds, and clinical decision making. This podcast was recorded and is being used with permission of the presenters. Learning Objectives Discuss recent evidence surrounding the use of biologic agents in the management of patients with COPD, including patient populations and outcomes Integrate the use of biologic agents into the management of patients with COPD based on guidelines and clinical evidence for new and emerging agents This activity is accredited for CME/CE Credit The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at [email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here. Disclosure of Commercial Support This educational activity is supported by an independent medical education grant from GSK and an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/adhd-sleep-and-symptom-control-10355 Summary Early-morning symptom control remains a critical gap in ADHD management, often contributing to family stress and impaired daily functioning. In this podcast/webcast activity, Dr. Joel Young and Jo Hughes, DMSc, PA-C, CAQ-PSY, explore the limitations of traditional ADHD medications in achieving full-day coverage and discuss available strategies to improve early-morning outcomes. Learners will gain practical insights into the clinical use of nighttime-dosed medications, including an innovative delayed-release/extended-release stimulant, and understand the pharmacologic characteristics that contribute to its efficacy in providing sustained symptom control. This podcast was recorded and is being used with permission of the presenters. Learning Objective Examine the ADHD treatment options that use nighttime dosing to achieve full-day symptom control This activity is accredited for CME/CE Credit This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at [email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here. Disclosure of Commercial Support This educational activity is supported by an educational grant from Collegium Pharmaceutical, Inc. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/personalized-antidepressant-choices-for-better-outcomes-in-mdd-10266 Summary Emphasizing a measurement-based, patient-centered model, this is an enduring podcast/webcast designed for psychiatrists who seek to refine their approach to managing major depressive disorder (MDD). Despite an expanding array of pharmacologic options, many patients continue to experience side effects and residual symptoms that undermine adherence and long-term recovery. Led by Drs. Gregory Mattingly and Gerald Maguire, this activity equips clinicians with evidence-based strategies to compare the nuanced risk–benefit profiles of antidepressants and apply them to individualized treatment plans. This podcast was recorded and is being used with permission of the presenters. Learning Objectives Assess the risk–benefit profiles of available antidepressants, including their impact on residual symptoms, to optimize treatment decisions for patients with MDD Implement personalized, measurement-based treatment strategies for patients with MDD to address residual symptoms, promote adherence, and improve outcomes This activity is accredited for CME/CE Credit This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.75 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at [email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here. Disclosure of Commercial Support This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik , provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications: 1. FDA change in Boxed Warning Label for Hormone Replacement Therapy. Discussion by: Guest: Anupriya Grover Wenk, DO Faculty - Family Medicine Residency Program Jefferson Health - Abington 2. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke – The New England Journal of Medicine 2025. Discussion by: Guest: Neil Skolnik, MD Professor of Family and Community Medicine Sidney Kimmel Medical College Thomas Jefferson University Associate Director - Family Medicine Residency Program Jefferson Health – Abington 3. AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program – JAMA. Discussion by: Guest: Neil Skolnik, MD Professor of Family and Community Medicine Sidney Kimmel Medical College Thomas Jefferson University Associate Director - Family Medicine Residency Program Jefferson Health – Abington 4. Incremental effect of healthy lifestyle habits when taking GLP-1 RA medications on Cardiac Risk Reduction. Discussion by: Guest: Joe Gonella, MD Resident– Family Medicine Residency Program Jefferson Health – Abington Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/personalizing-adhd-management-using-methylphenidate-10448 Summary Effective ADHD management demands more than symptom control—it requires personalized treatment strategies aligned with the patient’s unique daily functional needs. Through clinical case examples and pharmacologic comparisons, learners will explore how tailoring treatment using immediate-release (IR), extended-release (ER), and delayed-release/extended-release (DR/ER) methylphenidate (MPH) formulations can optimize symptom control aligned with patients’ daily routines and responsibilities. In this podcast/webcast activity, Joel Young, MD, and Jo Hughes, DMSc, PA-C, CAQ-PSY will highlight practical strategies for implementing personalized ADHD treatment plans, with a focus on the unique benefits of evening-dosed DR/ER-MPH in addressing early-morning and evening functional impairments. This podcast was recorded and is being used with permission of the presenters. Learning Objectives Evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of ER-, DR/ER-, and IR-MPH formulations to implement safe, effective, and personalized ADHD treatment decisions. Discuss individualization of ADHD treatment plans by selecting MPH formulations based on PK profiles, patient characteristics, and functional goals to optimize symptom control and adherence. This activity is accredited for CME/CE Credit This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at [email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here. Disclosure of Commercial Support This educational activity is supported by an educational grant from Collegium Pharmaceutical, Inc. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik , provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications: 1. Step Accumulation Patterns and Risk for Cardiovascular Events and Mortality Among Suboptimally Active Adults – Annals of Internal Medicine 2025. Discussion by: Guest: Kathryn Donnelly, DO Resident - Family Medicine Residency Program Jefferson Health - Abington 2. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Obesity – The New England Journal of Medicine 2025. Discussion by: Guest: Ajay Rau, MD Chief - Section of Endocrinology, Diabetes and Metabolism Lewis Katz School of Medicine at Temple University 3. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. New England Journal Of Medicine 2025. Discussion by: Guest: Jasmin Walker, MD Resident – Family Medicine Residency Program Jefferson Health – Abington Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik , provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications: 1. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity – The New England Journal of Medicine 2025. Discussion by: Guest: Anupryia Grover-Wenk, DO Resident - Family Medicine Residency Program Jefferson Health - Abington 2. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. – The New England Journal of Medicine 2025.Discussion by: Guest: Samantha Traslaviña, DO Resident– Family Medicine Residency Program Jefferson Health – Abington 3. Cycling and education intervention versus usual physiotherapy care for the treatment of hip osteoarthritis in the UK (CLEAT): a pragmatic, randomised, controlled trial. Lancet Rheumatology 2025. Discussion by: Guest: Sean Cleary, DO Resident– Family Medicine Residency Program Jefferson Health – Abington Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik , provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications: 1. Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial JAMA 2025. Discussion by: Guest: Philip Lieberman, MD Resident- Family Medicine Residency Program Jefferson Health - Abington 2. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. New England Journal of Medicine 2025 Discussion by: Guest: Donna Ryan, MD Professor Emerita at Pennington Biomedical Baton Rouge, LA, USA 3. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: a randomized, controlled clinical trial. Alzheimer’s Research & Therapy. Discussion by: Guest: Kathryn Donnelly, DO Resident– Family Medicine Residency Program Jefferson Health – Abington Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/personalizing-care-identifying-the-right-patients-for-new-treatments-10268 Summary Dr. Genevieve Neal-Perry and Dr. Andrea Singer focus on practical strategies in the personalized management of menopausal vasomotor symptoms (VMS). The discussion covers the importance of routine and individualized screening for VMS, with attention to healthcare disparities and the diverse ways menopause is discussed and experienced across populations, before covering patient selection criteria for newer non-hormonal treatments. Content Update Disclaimer : Since the recording of this and the accompanying podcast, the FDA has approved elinzanetant, an NK1/3 receptor antagonist for the treatment of menopausal VMS. This podcast was recorded and is being used with permission of the presenters. Learning Objectives Integrate routine and individualized screening methods to identify patients with menopausal VMS, with attention to healthcare disparities Integrate new and emerging agents into the treatment of women with menopausal VMS, based on patient characteristics and preference This activity is accredited for CME/CE Credit The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at [email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here. Disclosure of Commercial Support This educational activity is supported in part by an educational grant from Bayer HealthCare Pharmaceuticals Inc. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/targeting-cause-emerging-therapies-menopausal-vms-10267 Summary This enduring podcast activity explores groundbreaking advancements in the treatment of menopausal vasomotor symptoms (VMS), emphasizing non-hormonal therapies. Dr. Andrea Singer and Dr. Genevieve Neal-Perry discuss the underlying biology of menopause, particularly the role of neurokinin (NK) receptors, and introduces the science behind new therapeutic agents, as well as their clinical trial data. Content Update Disclaimer : Since the recording of this and the accompanying podcast, the FDA has approved elinzanetant, an NK1/3 receptor antagonist for the treatment of menopausal VMS. This podcast was recorded and is being used with permission of the presenters. Learning Objective Discuss the clinical trial data for new and emerging non-hormonal therapies This activity is accredited for CME/CE Credit The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at [email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here . Disclosure of Commercial Support This educational activity is supported in part by an educational grant from Bayer HealthCare Pharmaceuticals Inc. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik , provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications: 1. Antihypertensive Medication Timing and Cardiovascular Events and Death The BedMed Randomized Clinical Trial JAMA 2025. Discussion by: Guest: Susan Kuchera, MD Director of the Family Medicine Residency Program Jefferson Health - Abington 2. Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. 2025. Discussion by: Guest: Eden Miller, MD Diabetes and Obesity Specialist Bend, Oregon 3. As-Needed Albuterol–Budesonide in Mild Asthma. The New England Journal of Medicine. Discussion by: Guest: Dylan Selden, MD Resident– Family Medicine Residency Program Jefferson Health – Abington Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/strategies-and-real-world-impact-of-the-stimulant-crisis-10220 Summary The stimulant medication shortage has introduced new challenges in managing ADHD, affecting both patients’ access to essential treatments and clinicians’ ability to provide consistent care. In this PsychTalk podcast/webcast episode, Drs. Gregory Mattingly and Roger McIntyre explore the impact of these shortages, particularly on cognitive functioning, treatment continuity, and daily life for individuals with ADHD. Their discussion also examines stimulant misuse and diversion, looking at trends in medication sourcing, formulations most susceptible to abuse, and strategies to reduce the risk of misuse. By the end of the episode, learners will be equipped with timely insights and real-world tools to optimize ADHD management amid evolving supply and safety challenges. This podcast was recorded and is being used with permission of the presenters. Learning Objectives At the conclusion of this activity, participants should be better able to: Describe the impact of stimulant shortages on individuals with ADHD Incorporate best-practice clinical strategies to minimize the risk of stimulant misuse in the treatment of ADHD This activity is accredited for CME/CE Credit This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at [email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here. Disclosure of Commercial Support This activity is not supported by an educational grant. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: http://mycme.com/courses/the-cognitive-side-of-major-depressive-disorder-10221 Summary Despite significant improvements in mood symptoms, many patients with MDD continue to experience persistent residual symptoms—particularly cognitive impairments—that hinder full functional recovery. In this PsychTalk podcast/webcast episode, Drs. Gregory Mattingly and Roger McIntyre discuss the often-overlooked role of cognitive dysfunction in MDD recovery, highlighting how these impairments correlate strongly with reduced workplace productivity, social withdrawal, and elevated relapse risk, ultimately impeding long-term outcomes. Their conversation provides listeners with an in-depth understanding of the presentation of cognitive impairment and residual symptoms in MDD, as well as strategies to foster resilience, enhance patient engagement, and promote functional recovery. This podcast was recorded and is being used with permission of the presenters. Learning Objectives At the conclusion of this activity, participants should be better able to: Recognize the clinical significance of residual symptoms in MDD, with a focus on cognitive impairment, and their impact on patient functioning and treatment outcomes This activity is accredited for CME/CE Credit This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.25 hours of pharmacology). Summary of Individual Disclosures Please review faculty and planner disclosures here. Disclosure of Commercial Support This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/the-latest-data-in-ckd-progression-10197 Summary Emerging evidence highlights the potential of GLP-1 receptor agonists (GLP-1 RAs) to slow CKD progression and reduce cardiovascular and kidney-related mortality in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). Yet, despite updated guidelines, these therapies remain underused. This program will explore the latest clinical data supporting the role of GLP-1 RAs in risk mitigation and provide practical strategies for implementing guideline-based treatment to reduce cardio-renal risk and improve outcomes in patients with T2D and CKD. This podcast was recorded and is being used with permission of the presenters. Learning Objectives At the conclusion of this activity, participants should be better able to: Discuss emerging data on GLP-1 RA therapy for CKD progression in T2D Implement guideline-based care to minimize CV risk and CKD progression This activity is accredited for CME/CE Credit The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at [email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here . Disclosure of Commercial Support This activity is supported by an educational grant from Novo Nordisk. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik , provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications: 1. Effects of Combining Coronary Calcium Score With Treatment on Plaque Progression in Familial Coronary Artery Disease A Randomized Clinical Trial JAMA 2025. Discussion by: Guest: Michael J. Blaha, MD, MPH Professor of Cardiology and Epidemiology and presently serves as the Director of Clinical Research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease Director of the Cardiometabolic Clinic Program Director for the Preventive Cardiology Fellowship. 2. Creatine monohydrate pilot in Alzheimer’s: Feasibility, brain creatine, and cognition. Alzheimer’s Dement. 2025. Discussion by: Guest: Michael Devano, DO Attending Family Physician Christiana Care Health System 3. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. The New England Journal of Medicine. Discussion by: Guest: Joseph Gonnella, MD Resident– Family Medicine Residency Program, Jefferson Health – Abington Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/answers-in-chronic-spontaneous-urticaria-10190 Summary In this short CE/CME activity, moderator Dr. Brad Glick works with dermatology expert Dr. Gil Yosipovitch to answer your top questions regarding chronic spontaneous urticaria, as gathered from the 2025 NACE Conversations in Dermatology symposium. Questions cover diagnosis, treatment individualization, and more! Learning Objectives At the conclusion of this activity, participants should be better able to: Assess the disease burden and impact on QoL in patients with CSU Evaluate current and emerging therapies for CSU This activity is accredited for CME/CE Credit The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at [email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here . Disclosure of Commercial Support This activity is supported by an independent educational grant from Sanofi and Regeneron Pharmaceuticals. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/copd-inflammation-exacerbations-your-questions-answered-10143 Summary Rejoin the conversation on COPD, inflammation, and new and emerging agents as two of our expert faculty come together to answer your top questions. Questions submitted from the recent Conversations in Primary Care live virtual symposia guide the discussion as we dig a bit deeper on type 2 inflammation, changes in COPD management, and new and emerging agents – including recently approved biologic agents – for COPD. Learning Objectives At the conclusion of this activity, participants should be better able to: Review the relationship between inflammation, exacerbation, and disease progression in COPD, noting different inflammatory endotypes of patients with COPD Discuss recent evidence surrounding the use of biologic agents in the management of patients with COPD and type 2 inflammation Integrate current guidelines with clinical data on new and emerging agents for the management of COPD, distinguishing patients with and without markers of type 2 inflammation This activity is accredited for CME/CE Credit The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at [email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here . Disclosure of Commercial Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik , provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications: 1. Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) - New England Journal of Medicine 2025. Discussion by: Guest: Steven E. Nissen, M.D., Chief Academic Officer of the Heart and Vascular Institute at the Cleveland Clinic Professor of Medicine at the Lerner College of Medicine 2. Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline (2025). Discussion by: Discussion by: Guest: Anupriya Grover-Wenk, DO Faculty– Family Medicine Residency Program Jefferson Health – Abington 3. Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. Discussion by: Guest: Joseph Gonnella, MD Resident– Family Medicine Residency Program Jefferson Health – Abington Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/clinical-updates-in-schizophrenia-10097 Summary In this PsychTalk podcast/webcast episode, Drs. Gregory Mattingly and Lisa Harding go through the evolving landscape of schizophrenia treatments. Listen as they discuss the pros and cons of various second-generation antipsychotics, the science behind muscarinic modulation for psychosis, and recent updates in clozapine prescribing. At the end of the session, the doctors answer several audience questions to enhance your understanding of these developments and how they apply to clinical practice. This podcast was recorded and is being used with permission of the presenters. Learning Objectives At the conclusion of this activity, participants should be better able to: Integrate recent clinical data on antipsychotic treatments and relapse prevention strategies into management plans for patients with schizophrenia Describe the role of muscarinic modulation in psychosis This activity is accredited for CME/CE Credit This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.75 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at [email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here . Disclosure of Commercial Support This educational activity is not commercially supported. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.